No Data
Chunli Medical (688236) 2024 Third Quarter Report Review: Joint continuation labeling and sports medicine centralized procurement led to performance pressure
Subject: The company released the third quarter report of 24 years, Q1-3 24, operating revenue of 0.508 billion yuan (-35.84%), net income attributable to the parent company of 0.061 billion yuan (-66.14%), net profit after deducting non-recurring gains and losses of 0.044 billion yuan (-7
chunli medical (688236.SH): Cumulatively repurchased 0.226% of the company's shares.
Chunli Medical (688236.SH) announced on November 4th that, as of October 31, 2024, the company has repurchased a total of 868,145 shares through the Shanghai Stock Exchange's trading system via centralized competitive bidding trading method, accounting for 0.226% of the total share capital. The highest repurchase price was 15.96 yuan/share, the lowest price was 12.09 yuan/share, and the total amount paid was RMB 12,018,864.19 (excluding transaction costs).
Chunli Healthcare: Third Quarter Report 2024
Third Quarter Report 2024
chunli medical (01858) released its performance for the first three quarters, with a net income attributable to the mother of 61.1514 million yuan, a year-on-year decrease of 66.14%.
chunli medical (01858) released the third quarter report for 2024, achieving revenue of 0.508 billion during the period...
chunli medical (01858.HK) net profit for the first three quarters was 61.151 million yuan, a decrease of 66.14% year-on-year.
Grandway reported on October 30th that chunli medical (01858.HK) announced that the company's revenue in the first three quarters was 0.51 billion yuan, a decrease of 35.84% year-on-year; the net income attributable to shareholders of the listed company was 61.151 million yuan, a decrease of 66.14% year-on-year; and the basic earnings per share was 0.16 yuan.
No Data
No Data